ORGANIZATION

Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading

January 15, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pharma leader Joji Nakayama clarified himself on January 14 about his New Year remarks on the government’s tax plan, saying that he believes drug makers will be able to reap benefits from a revamped R&D tax credit system if it…

To read the full story

Pharma Biz Leader Airs Concern over Effective Tax Hikes
January 8, 2015

ORGANIZATION

Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…